Paul Tudor Jones Cullinan Oncology, Inc. Transaction History
Tudor Investment Corp Et Al
- $44 Billion
- Q2 2025
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 22,138 shares of CGEM stock, worth $167,363. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22,138Holding current value
$167,363% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CGEM
# of Institutions
153Shares Held
66.6MCall Options Held
10.6KPut Options Held
917K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$57.8 Million11.28% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$43.5 Million1.7% of portfolio
-
Lynx1 Capital Management LP San Juan, PR4.4MShares$33.3 Million9.81% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.86MShares$29.1 Million0.67% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$26.8 Million0.0% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $345M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...